LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Начало・Списък с акции・Editas Medicine Inc

Editas Medicine Inc

Затворен

СекторЗдравеопазване

2.52 -1.56

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.49

Максимум

2.54

Ключови измерители
By Trading Economics
Приходи	28M -25M
Продажби	4M 7.5M
Марж на печалбата	-332.984
Служители	246
EBITDA	27M -22M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+58.89% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-39M 236M
Предишно отваряне	4.08
Предишно затваряне	2.52

Настроения в новините

By Acuity

100%

359 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.33 / 1.54 Подкрепа & съпротива

Editas Medicine Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.12.2025 г., 22:53 ч. UTC

Придобивния, сливания и поглъщания

Fortescue to Take Full Control of US$101 Million Copper Miner Alta

13.12.2025 г., 00:04 ч. UTC

Придобивния, сливания и поглъщания

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

14.12.2025 г., 23:46 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Some Tailwinds -- Market Talk

14.12.2025 г., 23:36 ч. UTC

Пазарно говорене

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

14.12.2025 г., 22:38 ч. UTC

Придобивния, сливания и поглъщания

Fortescue to Take Full Control of US$101M Copper Miner Alta

14.12.2025 г., 22:02 ч. UTC

Придобивния, сливания и поглъщания

Fortescue: Transaction Is Consistent With Critical Minerals Strategy

14.12.2025 г., 22:01 ч. UTC

Придобивния, сливания и поглъщания

Fortescue: Alta Owns the Canariaco Project in Northern Peru

14.12.2025 г., 22:01 ч. UTC

Придобивния, сливания и поглъщания

Fortescue: Alta Directors Unanimously Recommend Proposal, Will Vote in Favor

14.12.2025 г., 22:00 ч. UTC

Придобивния, сливания и поглъщания

Fortescue: Agreement Implies Total Equity Value of C$139 Million

14.12.2025 г., 22:00 ч. UTC

Придобивния, сливания и поглъщания

Fortescue to Pay C$1.40/Share for Securities It Does Not Already Own

14.12.2025 г., 21:59 ч. UTC

Придобивния, сливания и поглъщания

Fortescue to Acquire Remaining 64% of Alta Copper

14.12.2025 г., 17:00 ч. UTC

Печалби

Tonka Trucks Gambled on Keeping Production in China and Survived -- Barely -- WSJ

14.12.2025 г., 08:30 ч. UTC

Придобивния, сливания и поглъщания

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

13.12.2025 г., 16:48 ч. UTC

Придобивния, сливания и поглъщания

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13.12.2025 г., 08:00 ч. UTC

Придобивния, сливания и поглъщания

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13.12.2025 г., 07:00 ч. UTC

Придобивния, сливания и поглъщания

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

13.12.2025 г., 00:24 ч. UTC

Придобивния, сливания и поглъщания

Want a Piece Of SpaceX? -- Barrons.com

12.12.2025 г., 23:49 ч. UTC

Придобивния, сливания и поглъщания

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12.12.2025 г., 22:52 ч. UTC

Пазарно говорене

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12.12.2025 г., 22:32 ч. UTC

Печалби

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

12.12.2025 г., 20:45 ч. UTC

Печалби

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12.12.2025 г., 20:41 ч. UTC

Пазарно говорене

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12.12.2025 г., 20:20 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12.12.2025 г., 19:23 ч. UTC

Печалби

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12.12.2025 г., 18:35 ч. UTC

Придобивния, сливания и поглъщания

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12.12.2025 г., 18:33 ч. UTC

Придобивния, сливания и поглъщания

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12.12.2025 г., 18:31 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12.12.2025 г., 17:49 ч. UTC

Печалби

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12.12.2025 г., 17:34 ч. UTC

Придобивния, сливания и поглъщания

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

Сравнение с други в отрасъла

Ценова промяна

Editas Medicine Inc Прогноза

Ценова цел

By TipRanks

58.89% нагоре

12-месечна прогноза

Среден 4.02 USD 58.89%

Висок 5 USD

Нисък 3 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Editas Medicine Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Editas Medicine Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.33 / 1.54Подкрепа & съпротива

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

There are no events.

Настроение

By Acuity

359 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.